Acella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
Acella Pharmaceuticals is recalling 154,726 bottles of NP Thyroid 15 tablets because they contain less active ingredient than labeled.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which is the highest severity level indicating a reasonable probability that use of the product will cause serious adverse health consequences or death.
Plain-English summary
Acella Pharmaceuticals, LLC is voluntarily recalling 154,726 bottles of NP Thyroid 15 (Levothyroxine, Liothyronine) tablets. The recall was initiated on April 29, 2021, and is classified as Class I by the FDA. The product is a prescription-only medication manufactured in Alpharetta, Georgia.
The reason for the recall is that the tablets are subpotent, meaning they contain less of the active thyroid hormone ingredients than stated on the label. The affected lots include M330D20-1, M330D20-2, M330J19-2A, M330J19-4A, M330J19-5A, M330J19-6A, M330J19-7A, M330J19-9A, M330K19-10, M330K19-1A, and M330K19-9. These lots have expiration dates ranging from August 31, 2021, to March 31, 2022.
The recalled product was distributed nationwide within the United States, including Puerto Rico. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the pharmacy or healthcare provider for disposal or replacement. The recall status is currently terminated.
The recalled product
- Product
- NP THYROID 15 (LEVOTHYROXINE, LIOTHYRONINE)
- Brand
- NP THYROID 15
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Thyroid Hormone
- Hazard
- Affected units
- 154,726
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (11)
- Lots: M330D20-1
- M330D20-2 Exp. 03/31/2022
- M330J19-2A
- M330J19-4A
- M330J19-5A
- M330J19-6A
- M330J19-7A
- M330J19-9A Exp. 08/31/2021
- M330K19-10
- M330K19-1A
- M330K19-9 Exp. 09/30/2021
UPCs (4)
- 0342192329102
- 0342192330108
- 0342192327016
- 0342192328013
Distribution
Part of a larger recall action
This product is one of 5 recalled by Acella Pharmaceuticals, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · NP THYROID 15
- CriticalAcella Pharmaceuticals Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine Levels
FDA (Drugs) · 2020-10-28
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02